StreetInsider.com News Articles

BofA Securities Downgrades LENZ Therapeutics Inc (LENZ) to Neutral

Wed, 12 Aug 2026 15:31:04 -0400

BofA Securities analyst Jason Gerberry downgraded LENZ Therapeutics Inc (NASDAQ: LENZ) from Buy to Neutral with a price target of $7.00 (from $31.00).

The analyst comments "We downgrade LENZ to Neutral and decrease our PO to $7 (from $31) effectively valuing the stock on its cash, on a slower-than-expected VIZZ presbyopia launch and more balanced risk/reward. LENZ remains a single-product biotech focused exclusively on commercialization of VIZZ eye drops. 2Q VIZZ product sales of $1.7m, essentially flat Q/Q, confirming only modest prescription-volume lift since launch. Underlying VIZZ volumes grew +9% Q/Q, outpacing revenue growth on minor GTN variability, but still representing

BofA Securities Downgrades LENZ Therapeutics Inc (LENZ) to Neutral

Wed, 12 Aug 2026 15:31:04 -0400

BofA Securities analyst Jason Gerberry downgraded LENZ Therapeutics Inc (NASDAQ: LENZ) from Buy to Neutral with a price target of $7.00 (from $31.00).

LENZ Therapeutics Inc (LENZ) PT Lowered to $7 at Piper Sandler

Wed, 12 Aug 2026 09:18:48 -0400

Piper Sandler analyst Biren Amin lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $7.00 (from $12.00) while maintaining a Neutral rating.

Citi cuts Lenz Therapeutics price target to $10 on slow sales

Wed, 12 Aug 2026 06:28:53 -0400

Citi analyst Yigal Nochomovitz lowered his price target on Lenz Therapeutics (NASDAQ: LENZ) to $10.00 from $20.00, while maintaining a Buy rating, citing weaker-than-expected commercial adoption of its VIZZ product.

Second-quarter 2026 product revenue came in at approximately $1.7M, below Citi and FactSet consensus estimates of approximately $2.5M. Volume grew roughly 9% sequentially, with approximately 27,000 packs sold, compared to Citi's estimate of approximately 37,500 packs.

Nochomovitz noted that management pointed to encouraging trends in July following a telehealth launch and a national television campaign, including prescription growth of more than 45% month-over-month, but added that "it is too early to conclude

LENZ Therapeutics, Inc. (LENZ) Tops Q2 EPS by 5c

Tue, 11 Aug 2026 16:17:28 -0400

LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported Q2 EPS of ($1.02), $0.05 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $2.49 million.

For earnings history and earnings-related data on LENZ Therapeutics, Inc. (LENZ) click here.

Form 10-Q LENZ Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260811/26905861.html

Form 10-Q LENZ Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260811/26905861.html

Form 8-K LENZ Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260811/26905726.html

Form 8-K LENZ Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260811/26905726.html

H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ)

Tue, 07 Jul 2026 07:04:11 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $38.00 price target on LENZ Therapeutics Inc (NASDAQ: LENZ).

The analyst commented: "To facilitate the current VIZZ launch trajectory as a novel topical ophthalmic alternative to reading glasses, the company has implemented a new telehealth prescribing option to accelerate patient access for appropriate prescriptions. With the VIZZ launch having just recently initiated in October 2025, we continue to believe the trajectory will play out over several quarters as prescribers and patients build progressive awareness and engagement with the product. We note the purpose of the new telehealth platform is to add

Form 8-K LENZ Therapeutics, Inc. For: Jun 30

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729209.html

Form 8-K LENZ Therapeutics, Inc. For: Jun 30

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729209.html

Form SCHEDULE 13G LENZ Therapeutics, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Fri, 26 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260626/26699648.html

Form SCHEDULE 13G LENZ Therapeutics, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Fri, 26 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260626/26699648.html

LENZ Therapeutics licenses VIZZ eye drop to Arrotex for Australia, NZ

Wed, 24 Jun 2026 08:32:01 -0400

LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. have entered into an exclusive license and commercialization agreement for VIZZ (aceclidine ophthalmic solution) 1.44% in Australia and New Zealand, according to a press release issued June 24, 2026.

Under the agreement, LENZ will receive an upfront payment and a profit share of gross margin from product sales. Arrotex will hold exclusive rights to register and commercialize VIZZ for the treatment of presbyopia in both countries. Specific financial terms were not disclosed.

VIZZ received U.S. Food and Drug Administration approval in July 2025 and has been commercially available in the United States

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

Wed, 24 Jun 2026 08:30:00 -0400

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ

SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

Wed, 24 Jun 2026 08:30:00 -0400

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: RA Capital Healthcare Fund LP

Mon, 15 Jun 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649137.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: RA Capital Healthcare Fund LP

Mon, 15 Jun 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649137.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Scheiner Zachary